Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (181-190 of 302) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancerC P Belani, C M Kearns, E G Zuhowski, et al.
Clinical Therapeutics|January 30, 2010
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction studyKarthik Venkatakrishnan, Michael Rader, Ramesh K Ramanathan, et al.
Seminars in Oncology|January 14, 1998
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagusC P Belani, J D Luketich, R J Landreaneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah, Ramesh K Ramanathan, David H Ilson, et al.
Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.
Clinical Colorectal Cancer|August 24, 2011
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancerRajesh Sehgal, Barry C Lembersky, Kiran K Rajasenan, et al.
Cancer|July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
British Journal of Clinical Pharmacology|March 25, 2020
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumoursDevalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2005
Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey A Sloan, Daniel J Sargent, et al.
Pageof 31

Showing results (181-190 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancerC P Belani, C M Kearns, E G Zuhowski, et al.
Clinical Therapeutics|January 30, 2010
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction studyKarthik Venkatakrishnan, Michael Rader, Ramesh K Ramanathan, et al.
Seminars in Oncology|January 14, 1998
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagusC P Belani, J D Luketich, R J Landreaneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah, Ramesh K Ramanathan, David H Ilson, et al.
Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.
Clinical Colorectal Cancer|August 24, 2011
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancerRajesh Sehgal, Barry C Lembersky, Kiran K Rajasenan, et al.
Cancer|July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
British Journal of Clinical Pharmacology|March 25, 2020
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumoursDevalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2005
Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey A Sloan, Daniel J Sargent, et al.
Pageof 31